Catch up on news from Murrieta Genomics by checking out our April 2020 newsletter here.
Blog
Like everyone, we are doing what we can to keep ourselves and those we love safe during this trying time.
Today we launched our newsletter, a monthly update to keep everyone in the loop. You can view it here.
John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with
Press Releases
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Blog
Catch up on news from Murrieta Genomics by checking out our April 2020 newsletter here.
Like everyone, we are doing what we can to keep ourselves and those we love safe during this trying time.
Today we launched our newsletter, a monthly update to keep everyone in the loop. You can view it here.
John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with
Press Releases
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will